Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Secukinumab Phase III Studies
Phase of Trial: Phase III
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 15 Sep 2017 Status changed from active, no longer recruiting to completed.
- 13 Sep 2017 Five year efficacy and safety data from this study presented at the 2017 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, Switzerland, according to a Novartis media release.
- 13 Sep 2017 Results published in a Novartis media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History